Long QT Syndrome: Genetic Testing for a Hidden Heart Risk

A seemingly healthy teenager collapses during a swim meet. A young woman faints after being startled by an alarm clock. An infant dies in their sleep with no explanation. In each case, the cause may be the same: a genetic condition called long QT syndrome (LQTS) that disrupts the heart's electrical system - often with zero warning signs until it's too late.

An estimated 1 in 2,000 people carry a genetic variant that causes long QT syndrome, though many will never know it (Schwartz et al., 2009). That makes LQTS one of the most common inherited cardiac conditions - and one of the most underdiagnosed. The good news? A simple genetic test can identify it, and once you know, the condition is highly treatable.

What Is Long QT Syndrome?

Every heartbeat depends on a precise sequence of electrical signals. Ions - primarily sodium, potassium, and calcium - flow in and out of heart muscle cells through tiny protein channels. This flow creates the electrical impulse that makes your heart contract, then resets the system for the next beat (Ackerman, 2015).

The "QT interval" is the time it takes your heart's electrical system to recharge between beats, measured on an electrocardiogram (ECG). In long QT syndrome, this recharging phase takes longer than normal. Think of it like a traffic light that stays yellow too long - eventually, something crashes.

When the QT interval is prolonged, the heart becomes vulnerable to a chaotic, rapid rhythm called torsades de pointes (French for "twisting of the points"). This can cause sudden fainting, seizures, or - in the worst cases - sudden cardiac arrest (Priori et al., 2013).

The Genetics Behind Long QT Syndrome

LQTS is primarily caused by mutations in genes that encode the ion channels controlling your heart's electrical activity. Over 17 genes have been linked to LQTS, but three account for roughly 90% of all genetically confirmed cases (Tester & Ackerman, 2014):

• KCNQ1 (LQT1) - Encodes the potassium channel responsible for the slow delayed rectifier current (IKs). Mutations reduce potassium flow out of heart cells, delaying repolarization. This is the most common type, accounting for about 30–35% of all LQTS cases (Napolitano et al., 2005).

• KCNH2 (LQT2) - Encodes the potassium channel for the rapid delayed rectifier current (IKr), also known as the hERG channel. Accounts for roughly 25–30% of cases (Napolitano et al., 2005).

• SCN5A (LQT3) - Encodes the cardiac sodium channel. Instead of reducing outward potassium flow, LQT3 mutations cause excess inward sodium current, keeping the heart cell charged too long. Accounts for 5–10% of cases but carries the highest risk of fatal events per episode (Priori et al., 2003).

The inheritance pattern is typically autosomal dominant, meaning you only need one mutated copy from either parent to be affected. Each child of a carrier has a 50% chance of inheriting the variant (Schwartz et al., 2012).

A rarer and more severe form, Jervell and Lange-Nielsen syndrome, is autosomal recessive - it requires two copies of a KCNQ1 or KCNE1 mutation and is associated with both LQTS and congenital deafness (Schwartz et al., 2006).

Why the Type Matters: Different Genes, Different Triggers

One of the most clinically important discoveries in LQTS research is that each genetic subtype has distinct triggers for cardiac events (Schwartz et al., 2001):

• LQT1: Exercise is the primary trigger, especially swimming. About 62% of cardiac events in LQT1 patients occur during physical exertion. Swimming is uniquely dangerous because it combines exercise with cold water exposure and face immersion (Schwartz et al., 2001).

• LQT2: Sudden auditory stimuli - alarm clocks, phone ringing, a baby crying - are classic triggers. Emotional stress and the postpartum period also increase risk. About 43% of events in LQT2 occur during emotional stress or sudden arousal (Schwartz et al., 2001).

• LQT3: Cardiac events tend to occur at rest or during sleep, making them especially dangerous because there's no warning and no one around to help. Though events are less frequent than LQT1 or LQT2, they are more likely to be fatal (Priori et al., 2003).

Understanding your specific genotype doesn't just explain your risk - it shapes your entire management plan, from which medications work best to which activities to modify.

Drug-Induced Long QT: When Medications Become Dangerous

Not all long QT syndrome is inherited. More than 200 commonly prescribed medications can prolong the QT interval, including certain antibiotics (azithromycin, fluoroquinolones), antidepressants (citalopram, escitalopram), antipsychotics (haloperidol, ziprasidone), anti-nausea drugs (ondansetron), and antiarrhythmics (sotalol, amiodarone) (Woosley et al., 2024).

Here's where genetics and pharmacology collide: people who carry "silent" LQTS variants - meaning their resting ECG looks normal - may experience dangerous QT prolongation only when exposed to one of these drugs. An estimated 5–20% of drug-induced QT prolongation cases involve an underlying genetic predisposition that was previously undetected (Roden, 2004). The website CredibleMeds maintains a regularly updated database of QT-prolonging medications.

This is a direct connection to pharmacogenomics - the science of how your DNA affects drug response. If you're curious about how your genetics influence medication safety more broadly, check out our pharmacogenomics guide.

How Genetic Testing for LQTS Works

Genetic testing for LQTS typically involves a multigene panel that sequences the major LQTS-associated genes. The Mayo Clinic's panel, for example, covers 10 genes including KCNQ1, KCNH2, SCN5A, CACNA1C, CALM1, CALM2, and CALM3 (Ackerman et al., 2011).

Who should get tested?

• Anyone with a QTc interval above 480 ms on ECG
• Anyone who has experienced unexplained fainting, especially during exercise, emotional stress, or sleep
• First-degree relatives (parents, siblings, children) of someone diagnosed with LQTS
• Families affected by unexplained sudden cardiac death in a young person
• Individuals with drug-induced QT prolongation out of proportion to the medication taken

Genetic testing identifies a causative mutation in approximately 75–80% of clinically diagnosed LQTS patients (Tester & Ackerman, 2014). Once a family's specific mutation is identified, cascade testing - screening each family member for that exact variant - becomes a simple, inexpensive yes-or-no test that can save lives.

If you've already done consumer DNA testing through services like 23andMe or AncestryDNA, your raw data file may contain some relevant variants, though consumer tests are not diagnostic for LQTS. You can upload your raw DNA data to GenomeInsight to explore what your existing results may reveal about cardiac and pharmacogenomic markers.

Treatment: What You Can Do About It

The most important thing about LQTS is this: once diagnosed, it is highly manageable. Treatments are guided by genotype (Priori et al., 2013):

• Beta-blockers are the first-line therapy for LQT1 and LQT2. Nadolol and propranolol are preferred over metoprolol, which has shown higher rates of breakthrough cardiac events (Abu-Zeitone et al., 2014). Beta-blockers reduce cardiac events by approximately 64% in LQTS patients overall, with the strongest benefit in LQT1 (Ahn et al., 2017).

• Mexiletine, a sodium channel blocker, is particularly effective for LQT3 because it directly addresses the excess sodium current caused by SCN5A mutations (Mazzanti et al., 2016).

• Implantable cardioverter-defibrillators (ICDs) are recommended for patients who experience cardiac arrest or recurrent fainting despite beta-blocker therapy.

• Left cardiac sympathetic denervation (LCSD) is a surgical option that reduces arrhythmia triggers for patients who can't tolerate medication or ICDs.

• Lifestyle modifications are genotype-specific: LQT1 patients should avoid competitive swimming and strenuous exercise. LQT2 patients should minimize sudden auditory stimuli (no alarm clocks next to the bed - use gradual-onset alarms). All LQTS patients should avoid QT-prolonging medications.

Key Takeaways

• Long QT syndrome affects roughly 1 in 2,000 people and is one of the leading genetic causes of sudden cardiac death in young, otherwise healthy individuals.
• Three genes - KCNQ1, KCNH2, and SCN5A - account for 90% of genetically identified cases.
• Each subtype has different triggers: exercise for LQT1, sudden noise/stress for LQT2, and rest/sleep for LQT3.
• Over 200 common medications can prolong the QT interval, and hidden genetic variants can make this dangerous.
• Genetic testing identifies the cause in ~80% of clinical cases, and cascade family testing can protect relatives.
• With proper treatment - primarily beta-blockers - LQTS is highly manageable, and the risk of sudden death drops dramatically.
• If you've done consumer DNA testing, upload your raw data to GenomeInsight to explore cardiac and pharmacogenomic insights, or subscribe to our newsletter for the latest in genomic health.

References

Abu-Zeitone, A., Peterson, D. R., Bhatt, A. B., Moss, A. J., Zareba, W., & Robinson, J. L. (2014). Efficacy of different beta-blockers in the treatment of long QT syndrome. Journal of the American College of Cardiology, 64(13), 1352–1358. https://doi.org/10.1016/j.jacc.2014.05.068

Ackerman, M. J. (2015). Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. Heart Rhythm, 12(11), 2325–2331. https://doi.org/10.1016/j.hrthm.2015.07.002

Ackerman, M. J., Priori, S. G., Willems, S., Berul, C., Brugada, R., Calkins, H., ... & Zipes, D. P. (2011). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm, 8(8), 1308–1339. https://doi.org/10.1016/j.hrthm.2011.05.020

Ahn, J., Kim, H. J., Choi, J. I., Lee, K. N., Shim, J., Ahn, H. S., & Kim, Y. H. (2017). Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: A meta-analysis. PLOS ONE, 12(10), e0185680. https://doi.org/10.1371/journal.pone.0185680

Mazzanti, A., Maragna, R., Faragli, A., Monteforte, N., Bloise, R., Memmi, M., ... & Priori, S. G. (2016). Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. Journal of the American College of Cardiology, 67(9), 1053–1058. https://doi.org/10.1016/j.jacc.2015.12.033

Napolitano, C., Priori, S. G., Schwartz, P. J., Bloise, R., Ronchetti, E., Nastoli, J., ... & Bhatt, A. (2005). Genetic testing in the long QT syndrome: Development and validation of an efficient approach to genotyping in clinical practice. JAMA, 294(23), 2975–2980. https://doi.org/10.1001/jama.294.23.2975

Priori, S. G., Schwartz, P. J., Napolitano, C., Bloise, R., Ronchetti, E., Grillo, M., ... & Bhatt, A. (2003). Risk stratification in the long-QT syndrome. New England Journal of Medicine, 348(19), 1866–1874. https://doi.org/10.1056/NEJMoa022147

Priori, S. G., Wilde, A. A., Horie, M., Cho, Y., Behr, E. R., Berul, C., ... & Tracy, C. (2013). HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm, 10(12), 1932–1963. https://doi.org/10.1016/j.hrthm.2013.05.014

Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10), 1013–1022. https://doi.org/10.1056/NEJMra032426

Schwartz, P. J., Crotti, L., & Insolia, R. (2012). Long-QT syndrome: From genetics to management. Circulation: Arrhythmia and Electrophysiology, 5(4), 868–877. https://doi.org/10.1161/CIRCEP.111.962019

Schwartz, P. J., Priori, S. G., Spazzolini, C., Moss, A. J., Vincent, G. M., Napolitano, C., ... & Bloise, R. (2001). Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation, 103(1), 89–95. https://doi.org/10.1161/01.CIR.103.1.89

Schwartz, P. J., Spazzolini, C., Crotti, L., Bathen, J., Amlie, J. P., Timothy, K., ... & De Jager, T. (2006). The Jervell and Lange-Nielsen syndrome: Natural history, molecular basis, and clinical outcome. Circulation, 113(6), 783–790. https://doi.org/10.1161/CIRCULATIONAHA.105.592899

Schwartz, P. J., Stramba-Badiale, M., Crotti, L., Pedrazzini, M., Besana, A., Bosi, G., ... & Spazzolini, C. (2009). Prevalence of the congenital long-QT syndrome. Circulation, 120(18), 1761–1767. https://doi.org/10.1161/CIRCULATIONAHA.109.863209

Tester, D. J., & Ackerman, M. J. (2014). Genetics of long QT syndrome. Methodist DeBakey Cardiovascular Journal, 10(1), 29–33. https://doi.org/10.14797/mdcj-10-1-29

Woosley, R. L., Heise, C. W., Gallo, T., Tate, J., Woosley, D., & Romero, K. A. (2024). QTdrugs List. AZCERT, Inc. https://crediblemeds.org

---

Related Reading

• heart disease genetic risk
• atrial fibrillation
• epilepsy and seizure genetics